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Background: MeCP2 (CpG-binding protein 2) is a nuclear multifunctional protein involved in several cellular
processes, like large-scale chromatin reorganization and architecture, and transcriptional regulation. In recent years,
a non-neuronal role for MeCP2 has emerged in cell growth and proliferation. Mutations in the MeCP2 gene have
been reported to determine growth disadvantages in cultured lymphocyte cells, and its functional ablation
suppresses cell growth in glial cells and proliferation in mesenchymal stem cells and prostate cancer cells. MeCP2
interacts with lamin B receptor (LBR) and with Heterochromatin Protein 1 (HP1) at the nuclear envelope (NE),
suggesting that it could be part of complexes involved in attracting heterochromatin at the nuclear periphery and
in mediating gene silencing. The nuclear lamins, major components of the lamina, have a role in maintaining NE
integrity, in orchestrating mitosis, in DNA replication and transcription, in regulation of mitosis and apoptosis and in
providing anchoring sites for chromatin domains.
In this work, we inferred that MeCP2 might have a role in nuclear envelope stability, thereby affecting the
proliferation pattern of highly proliferating systems.
Results: By performing knock-down (KD) of MeCP2 in normal murine (NIH-3 T3) and in human prostate
transformed cells (PC-3 and LNCaP), we observed a strong proliferation decrease and a defect in the cell cycle
progression, with accumulation of cells in S/G2M, without triggering a strong apoptotic and senescent phenotype.
In these cells, KD of MeCP2 evidenced a considerable decrease of the levels of lamin A, lamin C, lamin B1 and LBR
proteins. Moreover, by confocal analysis we confirmed the reduction of lamin A levels, but we also observed an
alteration in the shape of the nuclear lamina and an irregular nuclear rim.
Conclusions: Our results that indicate reduced levels of NE components, are consistent with a hypothesis that the
deficiency of MeCP2 might cause the lack of a key “bridge” function that links the peripheral heterochromatin to
the NE, thereby causing an incorrect assembly of the NE itself, together with a decreased cell proliferation and
viability.
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MeCP2 (Methyl CpG-binding protein 2) is widely stud-
ied in neuronal systems [1] since it acquired biomedical
importance with the discovery that mutations in its
gene, located at Xq28 in human, determined a profound
neurodevelopmental autism spectrum disorder, the Rett
syndrome (RTT) [2].
In the last years, a non-neuronal role for MeCP2 has
emerged in myofibroblast transdifferentiation and fibro-
sis [3,4], lung development [5] and cells growth. It has
been reported that MeCP2 mutation determines growth
disadvantage in cultured lymphocyte cells [6] and that
its functional ablation suppresses cell growth of glial
cells [7] and proliferation in mesenchymal stem cells [8]
and prostate cancer cells [9,10].
Besides, MeCP2 plays an important role in chromatin
remodelling [11] by binding to several proteins involved
in large-scale chromatin reorganization and architecture
[12,13]. MeCP2 and Heterochromatin Protein 1 (HP1)
[14], have been shown to concentrate in the pericentro-
meric heterochromatin, where they play a key structural
role and are involved in the control of gene expression
[15,16].
Polioudaki and co-workers [17] have shown that HP1
interacts with the nuclear envelope (NE) in an acetylation-
dependent manner, forming a quaternary complex with
the inner nuclear membrane protein LBR (lamin B-
binding receptor) and a sub-set of core histones (H3/H4),
which mediate their binding. Moreover, recent findings
indicate that MeCP2 interacts with LBR [18,19], sug-
gesting that MeCP2, HP1 and LBR could be part of a
complex involved in functional structures at the nu-
clear periphery.
The NE is composed of an outer nuclear membrane
(ONM), an inner nuclear membrane (INM), nuclear pore
complexes (NPCs), and nuclear lamina. The major com-
ponents of the lamina are intermediate filament-like pro-
teins, the nuclear lamins. Most adult mammalian somatic
cells contain three major lamins (A, B1 and C), as well as
several minor lamins (B2 and AΔ10). Separate genes en-
code lamins B1 and B2, whereas all of the A-type lamins
(lamin A and C) are encoded by a single gene and arise
through alternative splicing of a common transcript
[20,21]. Given their role in maintaining NE integrity, in or-
chestrating mitosis, in DNA replication and transcription,
in regulation of mitosis and apoptosis and in providing
anchoring sites for chromatin domains [22-24], lamins
and lamin-associted proteins represent essential and fun-
damental components for nuclear structure and nuclear
dynamics. Furthermore, cumulative data suggest that NE
proteins effect transcriptional silencing by recruiting chro-
matin with specific epigenetic marks and silencing factors
able to add new epigenetic modifications to chromatin
sequestered at the nuclear periphery [25].Mutations in the LMNA gene cause a variety of dis-
eases, from muscular dystrophy and lipodystrophy to
systemic diseases such as premature aging syndromes
[26]. Many data, moreover, support the idea that down
regulation, loss and/or specific mutations in lamins
cause abnormal nuclear shape [27,28], changes in het-
erochromatin localization at the nuclear periphery, glo-
bal chromatin reorganization, possibly specific changes
in the positions of genes and give rise to various condi-
tions termed laminopathies [29].
In this work, we inferred that MeCP2 might have a
role in nuclear envelope stability, thereby affecting the
proliferation pattern of highly proliferating systems.
Experiments were conducted to verify such hypothesis.
Results
Functional ablation of MeCP2 affects cells growth and
alters cycle progression
To investigate a possible role in cell cycle progression,
we performed knock-down (KD) of MeCP2 by siRNA in
normal murine (NIH-3 T3) and transformed human
prostate cells (PC-3 and LNCaP). As shown in Figure 1,
we observed a strong decrease in cell proliferation in
MeCP2 depleted PC-3, LNCaP and NIH-3 T3 cells.
While control cells displayed a typical exponential
growth, MeCP2 KD in PC-3 cells caused a strong alter-
ation of the growth rate and cell number. After seven
days of siRNA MeCP2 treatment PC-3 cells reached only
13%ca of control (Figure 1A) indicating that the absence
of MeCP2 might determine alteration in cell cycle pro-
gression. Similar results, with a 60%ca cell growth reduc-
tion in silenced MeCP2 cells have been obtained with
LNCaP and mouse embryo fibroblasts (NIH-3 T3)
(Figure 1B and 1C, respectively). These data are in
agreement with previous published results [9,10].
To further investigate possible defects during the cell
cycle, we performed FACS analysis of the MeCP2-
ablated PC-3 and control cells (at 3, 5 and 7 days after
the first transfection). Flow cytometry results underline
an alteration in the cell cycle progression of MeCP2-
depleted cells, with a reduction of the number of cells in
the G1-phase and a progressive increase of cells in sub-
G0/G1 (hypodiploid picks observed) and S- or G2M-
phases beginning at the 5th day of silencing, compare in
Figure 1: D1-D4; D2-D5; D3-D6.
To better evaluate these cell cycle alterations in 7day
siMeCP2 PC-3 cells, we detected the cell number in sub-
G0/G1 by FACS analysis and the cell number in S-G2/M
phases by bi-parametric FACS analysis (BrdU/PI incorp-
oration). We have estimated the sub-G0/G1 cell popula-
tion as non-cycling cells mentioned below the bar M1
(Figure 1 E1), and the quantitative analysis showed an
increase of about 10-15% of these cells (Figure 1 E2).
The results obtained after bi-parametric analyses (a
Figure 1 (See legend on next page.)
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Figure 1 MeCP2 ablation causes a defect in cell proliferation with a delay in cell-cycle progression. (A) PC-3, (B) LNCaP and (C) NIH-3 T3
cells were transfected with siRNA MeCP2 or non-targeting siRNA CTRL oligos; MeCP2 ablation was checked at 5 and 7 days after transfection and
PC-3, LNCaP and NIH-3 T3 cells, and cell proliferation was analysed (data are mean± SD bars calculated from three independent experiments). (D)
A representative FACS analysis of PC-3 treated with control siRNA (siRNA CTRL: plots 1, 2 and 3) or with siRNA against MeCP2 (siRNA MeCP2: plots
4, 5 and 6) that shows a delay in cell-cycle progression. (E) After 7 days of MeCP2 silencing was observed an enrichment of cells in sub-G0/G1
phase (M1 bar), a representative FACS analysis is shown in E1. The synthesis of three independent FACS experiments after 7 days of MeCP2
silencing is represented in bar chart E2 (statistics were performed using Student’s test. *: significant difference between siRNA CTRL and siRNA
MeCP2 PC-3 cells, P < 0.005). (F) A representative bi-parametric BrdU/PI FACS analysis of PC-3 cells after 7 days of MeCP2 silencing is shown in F1;
the synthesis of three independent bi-parametric BrdU/PI FACS analysis of PC-3 cells after 7 days of MeCP2 silencing is represented in bar chart
F2 (statistics were performed using ANOVA. *: significant difference in cell cycle phases between siRNA CTRL and siRNA MeCP2 PC-3 cells,
P < 0.05).
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crease of about 20% of cells in S-phase and a decrease of
15%ca in G1-phase as shown in Figure 1 F2.
Altogether, these results indicate that the MeCP2 de-
pletion produces a consistent reduction in cell prolifera-
tion together with a defect in the cell cycle progression
with an accumulation of cells in sub-G0/G1-, a decrease
in G1-, and an increase in S-phases.
MeCP2 silencing does not induce a severe apoptotic
and/or senescence effects
Decrease in cell proliferation associated to MeCP2 KD,
was combined with a strong cellular suffering visualized
by increased cytoplasmatic granularity and inclusions, ir-
regular nuclear shape and absence of cytoplasmatic extro-
versions (Figure 2A, right panel). All these morphological
characteristics added to the expression of β-galactosidase,
cell cycle arrest, and hypodiplod picks (observed in
siMeCP2 samples, Figure 1: D5 and D6 panels) are com-
patible with an apoptotic [30,31], or senescent phenotype
[32-35]. This prompted us to investigate whether the ab-
sence of MeCP2 would trigger these phenotypes. We car-
ried out transient knock-down of MeCP2 for 7 days and
apoptotic cell death and senescence were assessed in
MeCP2-silenced cells.
Increased apoptosis was observed in siRNA MeCP2
PC-3 cells as compared with control cells both at 5 and
7 days after the first transfection by Annexin V-FITC/
propidium iodide staining (Figure 2B: compare B1-B2;
B3-B4). In both conditions (siRNA CTRL and siRNA
MeCP2) the percentage of apopototic cells is low, reach-
ing a maximum of 12%ca 5 days after MeCP2 silencing
with a ratio of 2:1 of apoptotic cells between siRNA
MeCP2 and siRNA CTRL (Figure 2B, Annexin-positive
cells bar chart). Because of the low percentage of apop-
totic cells, to confirm the phenotype observed, we evalu-
ated the presence of the 89 kDa band of PARP that
appears after cleavage of Caspase-3, one of its main tar-
gets (Figure 2C) [36].
We further detected senescence after 7 days of MeCP2
silencing, as can be inferred by the presence of SA-β-
galactosidase positive blue cells in Figure 2D (compareuntreated cells in D1; siRNA CTRL cells in D2 and
siRNA MeCP2 in D3). In parallel, we also evaluated
senescence-associated heterochromatic foci (SAHFs) by
immunofluorescence (IF). This method measures changes
in chromatin structures by analysing the chromatin con-
densation (DAPI foci) that is enriched for heterochroma-
tin protein 1 (HP1) and histone H3 trimethylated on
lysine 9 (H3K9me3) [37]. In Figure 2E the white arrow, in
siRNA MeCP2 PC-3 cells, indicates a senescent cell with a
large morphology and SAHFs. The enlargement of each
stain DAPI (Figure 2E box a), HP1γ (Figure 2E box b) and
H3K9me3 (Figure 2E box c) is shown to better evaluated
the morphology.
Both SA-β-galactosidase and IF assays, suggest that
the senescent phenotype observed (5%ca of 7 day
siMeCP2 PC-3 cells, Figure 2D and 2E) might not be the
main cause of cell growth reduction.
Overall, our results indicate that MeCP2 absence
increases the percentage of senescent and apoptotic
cells, although these effects do not seem to account per
se for the strong reduction of cell number that we evi-
denced after 7 days of siRNA MeCP2 treatment.
MeCP2 silencing determines alteration of nuclear
envelope (NE)
Lower proliferation rates, tendency to senescence and
apoptosis can be associated to structural and functional
alteration of the nuclear envelope (NE) [38-41]. We,
therefore, hypothesized that alterations in the NE might
occur following MeCP2 depletion, thereby justifying the
observed variations in the cell cycle progression.
MeCP2 KD in PC-3 cells resulted in a considerable de-
crease in lamin A, lamin C, lamin B1 and LBR protein
levels (Figure 3A). Lamin B1 was also reduced both in
LNCaP and NIH-3 T3 cells (Figure 3A). Western blot
experiments were confirmed by RT-qPCR analysis of the
expression levels of the related genes in PC-3 cells
(Figure 3B). In summary, lamin A levels were reduced
up to 50%, while lamin C, lamin B1 and LBR levels were
approximately reduced of 30% - 40%.
Moreover, the immunofluorescence (IF) pattern of
lamin A was examined by confocal analysis in PC-3
Figure 2 (See legend on next page.)
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Figure 2 MeCP2 silencing determines PC-3 cells suffering without triggering a severe apoptotic and senescence effects. (A) Fixed PC-3
cells, transfected with siRNA CTRL or siRNA MeCP2 oligos were analyzed by confocal microscopy. Phase contrast representative pictures are
shown. (B)Annexin V-FITC/PI FACS analysis was performed in PC-3 cells after 5 and 7 days of MeCP2 RNAi. This staining reveals the amount of
early apoptosis (LR = A+ + PI-), late apoptosis (UR=A+ + PI+), living cells (LL = A- + PI-) and necrotic cells (UL =A+ + PI+); x-axis Annexin V stain signal,
y-axis PI stain signal. The percentage of apoptotic cells (UR+ LR) between control and siMeCP2 samples of different experiments is shown in
AnnexinV positive cells bar chart (statistic were performed using ANOVA. *: significant difference between siRNA CTRL and siRNA MeCP2 PC-3
cells after 5 days of silencing, P < 0.01. **: significant difference between siRNA CTRL and siRNA MeCP2 PC-3 cells after 7 days of silencing,
P < 0.001). (C) PC-3 cells were transfected with siRNA CTRL and siRNA MeCP2 oligos. After 7 days of transfection protein extracts were prepared
and western blot against Cleaved-PARP (Asp214 89 kDa) and GAPDH, as loading control, was performed. (D) SA-β-galactosidase assay was
performed at 7 days after the first MeCP2 silencing. Blue cells in (D1) untreated, (D2) siCTRL and (D3) siMeCP2 cells are shown. Bar chart shown
the percentage of senescent PC-3 cells after 7 days of siRNA CTRL (0.23%) and siRNA MeCP2 (4.4%) calculated by the ratio between the number
of senescent and non-senescent cells in different microscope fields (data are means ± SD bars). (E) Identification of SAHFs (senescence-associated
heterochromatic foci). Fixed 7day MeCP2 silenced PC-3 cells and control cells were treated with antibodies against HP1γ (green) and H3K9me3
(red) proteins and stained with DAPI. Cells were analysed using fluorescence microscope and an enlargement of each representative senescence
stain (indicated by the white arrow) is showed (box a, box b and box c). In bar chart is indicated the percentage of senescent PC-3 cells after 7
days of siRNA CTRL (1%ca) and siRNA MeCP2 (4%ca) calculated by the ratio between the number of SAHFs and total cells in different microscope
fields (data are means ± SD bars).
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(Figure 3C). These experiments confirmed the reduction
of lamin A levels, without visible changes in its nuclear
lamina localization. However, alterations in the shape of
the nuclear lamina and an irregular nuclear rim were evi-
dent in siMeCP2 cells respect to the controls (compare in
Figure 3C: panels 3 and 6, yellow arrows). These morpho-
logical abnormalities are reminiscent of features of
Hutchinson-Gilford Progeria Syndrome (HGPS) [42,43], a
rare premature aging disease caused by mutation in
LMNA gene. Although there are differences between
HGPS cells (LAΔ50/progerin) and MeCP2 KD cells
(lamin A/C, lamin B1, LBR low levels), it is interesting to
underline that, although non-overlapping, share a number
of common traits [44].
We also estimated the local intensity distribution of
MeCP2 and lamin A proteins; three representative
cells are shown (Figure 3C: box1 of panel 3; box2
and box3 of panel 6). The siRNA CTRL cell in box1
of panel 3 of Figure 3C displays the endogenous
levels of MeCP2 and lamin A, which are quantified in
the top line diagram of Figure 3D. In addition, the
same cell at the phase-contrast image (Figure 3C:
panel 3a, black arrow) shows a normal nuclear shape.
The mean fluorescence intensity levels of cell in box2
(MeCP2-siRNA treatment, Figure 3C: panel 6) show a
reduction of lamin A after MeCP2 silencing (for the
fluorescence intensity see Figure 3D, bottom line dia-
gram). The same cell in the phase-contrast image
(Figure 3C: panel 6a, black arrow) exhibits the char-
acteristic nuclear shape of a suffering cell. Finally, the
cell in box3 (siRNA MeCP2 treatment, Figure 3C:
panel 6) represents an intermediate condition, in
which a partial MeCP2 silencing is coupled with a
partial lamin A depletion, without affecting nuclear
shape. The line diagram of the cell in box 3 is shown in
Figure 3E. This condition is also evidenced in panel 6a(white arrow) of Figure 3C, where the same cell only
shows early signs of nuclear suffering.
In summary, our data indicate that the absence of
MeCP2 markedly impairs nuclear envelope stability and
shape by affecting the expression levels of key proteins
(lamin A, lamin C, lamin B1 and LBR), suggesting that
the decrease in cell proliferation observed in the absence
of MeCP2 might be due to this effect. Besides, we can
speculate that the apoptotic and senescence phenotypes
observed in MeCP2 ablated PC-3 cells might be a conse-
quence of nuclear envelope instability. However, we can-
not exclude that the combination of all the phenotypes
observed (apoptosis, senescence and alterations of NE)
could cooperate on the whole to determine the strong
reduction in the proliferation of PC-3 cells.
Discussion
In this study, we have shown that the KD of MeCP2
determines a dramatic reduction in cell proliferation,
combined with a strong decrease in the expression of
nuclear envelope (NE) components, i.e. lamin A, C and
B1 and LBR. We also detected some degree of apoptosis
and senescence, as observed by other Authors [8,10],
which however did not appear to be the main causes of
the cell proliferation defect we encountered. It must be
noted that ablation of MeCP2 produces different effects
in relation to the cellular system under consideration.
For example, is the previous work of Squillaro et al., [8]
in human mesenchymal stem cells (MSCs) where a par-
tial silencing of MeCP2 in MSCs induces a significant
reduction of S-, along with an increase in G1-phase cells
accompanied by a reduction of apoptosis, the triggering
of senescence, a decrease in telomerase activity and the
down-regulation of genes involved in maintaining of
stem cell properties. In these cells senescence appeared
to rely on impairment of DNA damage repair and
seemed to occur through RB- and P53 related pathways.
Figure 3 MeCP2 functional ablation determines alteration of NE components expression. (A) PC-3, LNCaP and NIH-3 T3 cells were
transfected with siRNA CTRL and siRNA MeCP2 oligos. Protein extracts were prepared at 5 and 7 days after transfection. Western blot assays
against MeCP2 (70 kDa), lamin A/C (69 kDa, 62 kDa respectively), lamin B1 (68 kDa), LBR (58 kDa) and GAPDH (34 kDa), as loading control, were
performed. (B) Quantitative RT-PCR showed that 7 days of MeCP2 silencing in PC-3 cells causes alteration of mRNA levels of LMNA, lamin B1 and
LBR genes. mRNAs levels were normalized with respect to GAPDH housekeeping gene and were expressed as arbitrary units (statistics were
performed using Student’s test. *: significant difference between siRNA CTRL and siRNA MeCP2, P < 0.001; °, significant difference between siRNA
CTRL and siRNA MeCP2, P < 0.05). (C) Intracellular localization of endogenous lamin A and MeCP2 proteins. Fixed 7day MeCP2 silenced PC-3 cells
and control cells were treated with antibodies against MeCP2 (green) and lamin A (red) proteins and analysed by confocal microscopy. Low
levels of MeCP2 protein do not alter lamin A distribution, however an irregular nuclear rim is observed (C3-C6; C3a-C6a fluorescent and phase
contrast images respectively). (D) In the line diagram is shown the local intensity distribution (diagonal white lines through the images) of MeCP2
(green), lamin A (red) in box1 (siRNA CTRL cell) and in box2 (siRNA MeCP2) respectively. (E) In the line diagram is shown the local intensity
distribution of MeCP2 (green) and lamin A (red) of cell in box3.
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cancer PC-3 cells express a distinct pattern of proteins
involved in cell cycle control with a defective G1 checkpoint
[45-47], allowing these cells to enter S-phase. PC-3 cells
present a functional mitotic spindle checkpoint [48] that
requires a functional nuclear lamina. Therefore, in MeCP2
ablated cells, where the lamins are knock down, progression
into G2/M might be precluded [49].
The NE creates a barrier between the nucleoplasm
and the cytoplasm and constitutes a central element of
intracellular architecture. Furthermore, NE components
are essential for proper cell proliferation and actively
participate in mitotic progression, revealing a tight inter-
play between NE components and the mitotic machinery
[23,50]. In this view, the marked decrease in cell prolif-
eration and changes in cell cycle progression observed
following MeCP2 ablation could be explained by anom-
alous expression of NE components, with a consequent
defect in the architecture of the nuclear envelope, rather
than by an increase in apoptosis and/or senescence, phe-
notypes which might take over later. Although MeCP2
is largely known as a transcriptional repressor [51],
KD of this protein in our experiments determines a
decrease in levels of NE components, suggesting that
MeCP2 might act either indirectly, for example by
repressing transcriptional-repressor protein(s) of NE
target genes, or directly as a transcriptional activator
as previously suggested [52].
Lamin-depleted envelopes are extremely fragile and
fail to grow beyond a limited extent highlighting that
lamins play an essential role in later growth and in
maintaining the structural integrity of the envelope. In
fact, at the end of mitosis nuclear assembly occurs firstly
by formation of an envelope capable of regulating
nuclear-cytoplasmic transport and then the assembly of
the lamina completes this initial envelope. During inter-
phase, the lamina plays an essential role in maintaining
the shape, volume and stability of the NE [49,53].
Dynamic reorganization of the NE is also essential
for chromosome segregation during mitosis and res-
toration of the nuclear compartment in the daughter
cells. During mid-late S-phase, B-type lamins are
associated with the elongation phase of DNA replica-
tion, in agreement with the observation that B-type
lamins, proliferating cell nuclear antigene (PCNA)
and BrdU colocalise in nucleoplasmatic foci in cul-
tured mammalian cells [54]. Moir and co-workers
[55] also demonstrated that during the anaphase-
telophase transition, lamin B1 begins to associate to
the surface of the chromosomes. Finally, during the
transition from late cytokinesis into G1 lamin B1 rapidly
encloses the entire perimeter of the region containing
decondensing chromosomes in each daughter cell. There-
fore, the failure in cell proliferation following MeCP2silencing could be explained by the decreased amount of
lamins, which can contribute to generate defective NEs
during S-, G2/M-phases and alterations in shape and resist-
ance to mechanical stress of the NEs in the following cell
cycle.
NE has scaffolding functions for the formation and
regulation of higher order chromatin organization and in
epigenetic regulatory pathways. Previous results point to
the interaction between chromatin modifiers, epigenetic
regulators, chromatin architectural organizers and NE
components. In particular, the NET (Nuclear Envelope
Transmembrane) protein LBR (Lamin B-binding Recep-
tor) forms a quaternary complex with HP1 and H3/H4
histones [17] and binds to peripheral heterochromatin as
a higher oligomer, thereby creating distinct nuclear enve-
lope microdomains [56] involved in chromatin remodel-
ling and transcriptional inactivation [57]. Besides, MeCP2
interacts with HP1 during differentiation within the het-
erochromatin regions [14] and, as already noted, MeCP2
binds LBR [18,19]. Thus, the results of this paper, together
with data previously reported by our group [18], are con-
sistent with a hypothesis that the deficiency of MeCP2
might cause the lack of a key “bridge” function that links
the peripheral heterochromatin to the NE, accounting for
a role of this protein in mediating the distribution of het-
erochromatin fractions at the nuclear periphery linked to
the inner membrane.Conclusion
In summary, our results suggest that in absence of MeCP2
cells have reduced levels of NE components, such as
lamins and LBR, thereby losing their ability to correctly
assemble their NE, together with decreased in cell prolif-
eration and viability. MeCP2 might be an important
“bridge” protein between nuclear envelope and chromatin,
providing chromatin stability at the nuclear periphery.
MeCP2 could be involved in regulating the expression of
NE components, ensuring that adequate levels are present
to maintain proper NE organization. Further studies are
necessary to better investigate, and to strengthen the evi-
dence for this novel interesting role of MeCP2 and the in-
triguing link between this multifunctional protein and the
architecture and organization of the NE.Methods
Cell culture and transfection
PC-3 and LNCaP cells (ATCC) were cultured in
RPMI 1640 (EuroClone) supplemented with 10% FCS
(EuroClone) and 1X L-glutamine (PAA) and 1X
Penicillin-Streptomycin (PAA). NIH-3 T3 cells (ATCC)
were cultured in Dulbecco’s Eagle’s medium high glucose
(DMEM) supplemented with 10% FCS (EuroClone) and
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(PAA).
Human or mouse MeCP2 RNA sequences (On-
TARGETplus™ SMARTpool, Dharmacon RNA Tech-
nologies) and Non-targeting Pool (Dharmacon) were
transfected with INTERFERin™ siRNA transfection re-
agent (Polyplus transfection) according to the manufac-
turer’s recommendations.
Cell proliferation
PC-3, LNCaP and NIH-3 T3 cells were transfected with
human/mouse MeCP2 SMARTpool (siRNA MeCP2) or
Non-targeting Pool (siRNA CTRL) sequences. Six-wells
plates were seeded with 4 × 104 PC-3 cells per well, 8 × 104
LNCaP cells per well and 3 × 104 NIH-3 T3 cells and trans-
fected the day after. All cell lines were retransfected at 3
and 5 days after the first transfection (total of three follow-
ing transfections) and counted at 3, 5 and 7 days of
silencing.
Cell cycle analysis
For cell cycle analysis, PC-3 cells transfected (total
time 7 days) were fixed in ice-cold 70% ethanol,
washed in 1X PBS buffer, and treated with 20μg/ml
RNaseA and 50 μg/ml Propidium Iodide (SIGMA-
Aldrich St.Louis-MO) for 30 min at RT prior to ana-
lysis of 1 × 104 cells with FACSCalibur flow cyt-
ometer (Becton-Dickinson, Franklin Lakes, NJ, USA).
Data were processed using CellQuest software (Bec-
ton-Dickinson).
Bi-parametric analysis
PC-3 cells were transfected for 7 days using human siRNA
MeCP2 or human siRNA CTRL SMARTpool oligos, as
described above. Cells were incubated with bromodeox-
yuridine (BrdU; 10 μM for 30 minutes), harvested and
fixed in ice-cold 70% ethanol. 1 × 106 cells were exposed
to 2 N HCl for 30 minutes at room temperature and, after
centrifuge, to 0.1 M of Na2B4O7 10H2O (pH=8.5) for 10
minutes. After centrifuge, cells were resuspended in
0.5% Tween20/1% BSA/PBS 1X solution and incu-
bated with anti-BrdU antibody (Becton Dickinson) at
room temperature for 45 minutes. After centrifuge,
cells were resuspended in 50 μl of 0.5% Tween20/1%
BSA/PBS 1X solution added with anti-mouse FITC anti-
body (Alexa Fluor 488 F(ab’)2 fragment of goat anti-
mouse IgG), 1:50 diluted, and incubated at room
temperature for 30 minutes. Cells were centrifuged and
resuspended in PBS 1X solution, treated with 20 μg/ml
RNaseA and 5 μM Propidium Iodide (SIGMA-Aldrich St.
Louis-MO) for 1 hour at RT, and analysed by FACSCali-
bur flow cytometer (Becton-Dickinson, Franklin Lakes,
NJ, USA). Data were processed using CellQuest software
(Becton-Dickinson). The distribution of green fluorescencefrom FITC, expressed on a logarithmic scale, was collected
as a measure of BrdU incorporation, and the distribution of
red fluorescence from PI, on a linear scale, was collected as
a measure of DNA content.
Annexin V assay (apoptosis detection)
PC-3 cells were silenced using human MeCP2 siRNA
SMARTpool. Six-well plates were seeded with 4 × 104
PC-3 cells per well and 24 hours after were silenced for
7 days (three subsequent transfections were performed,
PC-3 were counted at 3, 5 and 7 days). At each counter
passage, cells were prepared for cell cycle analysis (FACS
preparation, see below) and Western blot assay (see
below).
Apoptosis detection was performed using Annexin V-
FITC Apoptosis Detection Kit (BD Pharmingen) by
FACS assay.
SA-β-galactosidase assay (cellular senescence detection)
PC-3 siMeCP2 transfected cells were tested for senes-
cence using SA-β-galactosidase assay (Cellular Senes-
cence assay Kit, Chemicon International-MILLIPORE)
according to the manufacturer’s instructions.
Western blot analysis and antibodies
Western blotting analyses were carried out using whole
cell extracts obtained using Leammli buffer 2X, sepa-
rated on 8–14% SDS-PAGE gels, and transferred to
nitrocellulose membranes. Membranes were incubated
with the following primary antibodies: anti-MeCP2
rabbit polyclonal (1:500 dilution, M 9317 SIGMA-
Aldrich), anti-laminA/C goat polyclonal (1:500 dilution,
sc-6215, SantaCruz Biotech., Santa Cruz, CA), anti-
laminB1 goat polyclonal (1:500 dilution, c-20, Santa
Cruz), anti-LBR rabbit polyclonal (1:2000 dilution, Cov-
ance Research Products INC), anti-Cleaved PARP
(Asp214) rabbit polyclonal (1:1000 dilution, Cell Signal-
ing Technology, Inc.). The corresponding peroxidase-
labeled secondary antibody (Jackson ImmunoResearch,
Laboratories, INC.) was detected using ECL western
blotting reagents (sc-2048 Santa Cruz biotechnology,
INC). Equal loading were checked out by GAPDH (anti-
GAPDH rabbit polyclonal 1:2000 dilution, Open Biosystems).
Immunofluorescence microscopy
PC-3 siRNA MeCP2 transfected cells were washed with
1X PBS buffer, fixed with 4% paraformaldehyde, permea-
bilized with 0.1% Triton X-100 (room temperature,
10 min) and blocked using 1X PBS buffer with 2% BSA,
30 min. In order to detect endogenous MeCP2 or lamin
A proteins, cells were incubated with anti-MeCP2 rabbit
polyclonal antibody (1:500 dilution, M9317 SIGMA) or
with anti-lamin A mouse monoclonal antibody (1:500 di-
lution, Abcam Cambridge, UK) for 60 min. In order to
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anti-HPγ mouse monoclonal antibody and anti-H3 (tri-
methylK9) rabbit polyclonal (both 1:100 dilution, Abcam
Cambridge, UK). The coverslips were washed and incu-
bated with secondary antibody conjugated to Cy™3-con-
jugated Affinity Donkey anti-rabbit antibody (1:500
dilution, Jackson ImmunoResearchLaboratories, INC) or
Cy™2-conjugated Affinity Donkey anti-mouse antibody
(1:500 dilution, Jackson) for 60 min. Cells were washed
twice and incubated with DAPI, rinsed in 1X PBS. Fi-
nally, coverslips were washed and mounted with Moviol
fluorescent mount. NE Images were acquired on a Zeiss
LSM410 laser scanning confocal microscope using the
63X objective lens; senescent phenotype images were
analysed with a fluorescence microscope (BX51; Olym-
pus, Melville,NY; equipped with UplanIF 40X/0.75) and
pictures were acquired with a colour camera (DP50;
Olympus).
RT-qPCR analysis
Primers to be used in RT-qPCR experiments were
designed with on-line Primer3 software (http://frodo.
wi.mit.edu/) choosing amplicons of approximately 75-
135 bp (see Additional file 1: Table S1). The selected
sequences were tested against public databases (NBLAST)
to confirm the identity of the genes.
PC-3 cell cultures were collected and lysed by addition
of RP1 buffer (NucleoSpin TriPrep kit, Macherey-Nagel
GMbH&Co.KG, Germany) and total RNA was isolated.
To prevent genomic DNA contamination rDNaseI (RNase-
free) was used according to the manufacturer’s instructions
(NucleoSpin TriPrep kit, Macherey-Nagel GMbH&Co.KG,
Germany). Quality of the total RNA was assessed
using a Nanodrop (with A260/280 around 1,9-2,00) and
on gel. 2 μg of total RNA were reverse-transcribed in
20 μl using SuperScript III First-Strand (Invitrogen)
with oligo-dT primer, according to manufacturer’s
instructions. cDNA was diluted 1:10 and subsequent
real-time PCR reactions were carried out on a PTC-
200 cycler (MJ Research). Real-time PCR were per-
formed with 1X iQ™SYBR Green Supermix (BioRad)
and 100nM primer forward and 100nM primer re-
verse final concentrations. In brief, the qPCR mix-
tures were pre-heated at 95°C for 10 min, followed by
40 cycles of amplification (95°C for 15 s, 58°C for
1 min, 80°C for 30 s) and melting curves analyses
(from 60.5°C to 90°C, read every 0.5°C, hold 5 s).
Blank (No Template Controls) and noRT controls
were run for detecting PCR and DNA contamination,
respectively. Data were analysed by averaging quadru-
plicates Cq. Levels of RNA expression were deter-
mined by Gene Expression Analysis for iCycler iQ
Real-Time PCR Detection System v1.10 (Bio-Rad)
according to the 2-ΔΔCq method. Levels of RNAexpression of selected genes were normalised to the
internal control GAPDH.
Statistical analysis
Statistical analyses of the data were performed by two-way
ANOVA, with Bonferroni’s post-test for multiple compari-
sons, or Student’s t test, using Prism 4.03 (GraphPad Soft-
ware, Inc., San Diego, CA, USA).
Additional file
Additional file 1: Table S1. Table of qPCR primers used.
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